Search results
US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WSB Radio· 1 day agoWASHINGTON — (AP) — Federal regulators are challenging patents on 20 brand-name drugs, including the...
Wegovy Is Available Again After Shortages, FDA Says—But Supplies Are Still Limited
Forbes· 2 days agoThe 1.7 milligram (mg) dose of Wegovy is listed as available on the FDA’s drug shortage database...
FTC Targets ‘Junk’ Patent Listings on Ozempic and Other Drugs
The Wall Street Journal· 1 day agoThe crackdown is the latest assault against what the agency regards as drugmakers’ patent ploys...
Weight loss drugs like Wegovy have taken the country by storm. But who can afford them?
USA TODAY via Yahoo Finance· 7 days agoPatients like Price are struggling to afford a blockbuster class of weight-loss medications called...
Chasing Novo and Lilly: The obesity drugs that could challenge Wegovy and Zepbound
BioPharma Dive via Yahoo Finance· 2 days agoLarge and small drugmakers are vying for a piece of what analysts view as one of the biggest market...
British pharmacies vie for weight-loss patients with drug price cuts
Reuters via Yahoo News· 3 hours agoOnline pharmacies and slimming clinics are cutting prices for Wegovy and Mounjaro in Britain just...
Drugmakers Exposed to Antitrust Probes if Patent Cache Adopted
Bloomberg Law· 23 hours agoA proposed patent office depository for sealed settlements could expose pharmaceutical giants to antitrust scrutiny if investigators use it to identify which companies may have coaxed biosimilar ...
Drugmakers, hospitals spar over new 340B drug discount 'dispute resolution' process
BenefitsPRO· 6 days agoThe new dispute resolution process is designed to use government officials to oversee disagreements,...
Judge rejects J&J, BMS challenges to Medicare drug pricing program
NJBIZ· 14 hours agoA federal judge in New Jersey tossed lawsuits from Johnson & Johnson and Bristol Myers Squibb...
FTC targets ‘junk patents’ on Ozempic, other top drugs
BioPharma Dive via Yahoo Finance· 20 hours agoThe move broadens the antitrust regulator’s campaign against allegedly “improper or inaccurate”...